I typed out some of the key points from Nader's Mo
Post# of 154977
(Total Views: 338)
Posted On: 05/21/2019 5:16:59 PM
Re: Evil Rabbit #3259
I typed out some of the key points from Nader's Money Talk Station radio interview during the pertinent financing part of the convo. Nothing much new from the shareholder CC but thought I'd recap for those who don't have time to listen...
- - - -
Interviewer: "How are you financing the company...?"
Nader:
Because we're in OTCBB we're not getting recognition for our stock, so we need to get to revenue.
To get to revenue we need $28m to get to end of year.
We have 145 million warrants out there. We've offered 40 cents a share and 1/2 share extra. If everybody exercises, we'll have over $50m which will get us to revenue.
We're also talking about licensing deals and partnerships that could get us to a cash surplus this year. If any of these pan out, we are in great shape.
We really think we are on the brink of getting a good deal for our shareholders, including commercialization company, which has given us an offer for milestone payments and small upfront payment, and they are ready to increase upfront payments substantially.
We have non-binding term sheet with Chinese company for $20m upfront and another $10m to form a China branch of Cytodyn.
We have other potential deals with other pharmas who want licensing agreements with HIV, GVHD, NASH.
We will also have prostate deal license agreement at anytime.
- - - -
Interviewer: "How are you financing the company...?"
Nader:
Because we're in OTCBB we're not getting recognition for our stock, so we need to get to revenue.
To get to revenue we need $28m to get to end of year.
We have 145 million warrants out there. We've offered 40 cents a share and 1/2 share extra. If everybody exercises, we'll have over $50m which will get us to revenue.
We're also talking about licensing deals and partnerships that could get us to a cash surplus this year. If any of these pan out, we are in great shape.
We really think we are on the brink of getting a good deal for our shareholders, including commercialization company, which has given us an offer for milestone payments and small upfront payment, and they are ready to increase upfront payments substantially.
We have non-binding term sheet with Chinese company for $20m upfront and another $10m to form a China branch of Cytodyn.
We have other potential deals with other pharmas who want licensing agreements with HIV, GVHD, NASH.
We will also have prostate deal license agreement at anytime.
(0)
(0)